Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 147
Filter
1.
Opt Lett ; 48(12): 3295-3298, 2023 Jun 15.
Article in English | MEDLINE | ID: mdl-37319085

ABSTRACT

In this Letter, we present and explain novel radiation properties enabled by defects in resonant photonic lattices (PLs). Incorporating a defect breaks the lattice symmetry and generates radiation through the stimulation of leaky waveguide modes near the non-radiant bound (or dark) state spectral location. Analyzing a simple one-dimensional (1D) subwavelength membrane structure, we show that the defects produce local resonant modes that correspond to asymmetric guided-mode resonances (aGMRs) in spectra and near-field profiles. Without a defect, a symmetric lattice in the dark state is neutral, generating only background scattering. Incorporating a defect into the PL induces high reflection or transmission by robust local resonance radiation depending on the background radiation state at the bound state in the continuum (BIC) wavelengths. With the example of a lattice under normal incidence, we demonstrate defect-induced high reflection as well as high transmission. The methods and results reported here have significant potential to enable new modalities of radiation control in metamaterials and metasurfaces based on defects.

2.
Opt Lett ; 48(2): 311-314, 2023 Jan 15.
Article in English | MEDLINE | ID: mdl-36638445

ABSTRACT

The properties of periodic optical lattices are generally investigated with rigorous numerical methods. For physical insight and understanding of the complex processes underlying observed spectra, simple analytical models are needed. Accordingly, we show that by applying full Rytov effective-medium formalisms, the bound and leaky states of resonant photonic lattices can be quantified with high precision. Thus, all key properties are embodied in Rytov-equivalent homogeneous waveguides. The symmetric effective-medium theory (EMT) model quantifies rigorously computed guided-mode resonance (GMR) reflectance loci defining the leaky states. The asymmetric EMT formula similarly quantifies the bound state in the continuum (BIC) loci. Even with the period and wavelength on similar scales, the analytical EMT refractive index solutions agree exactly with rigorous solutions. We apply the Rytov formulas to explain the resonant leaky band structure including appearance of GMR and BIC states as well as band transitions and band closure points. The wavenumbers of the equivalent waveguides represent the BIC embedded eigenvalues as quantified here.

3.
Med Oncol ; 39(9): 121, 2022 Jun 18.
Article in English | MEDLINE | ID: mdl-35716210

ABSTRACT

The small molecule 3-bromopyruvate (3BP), is an anticancer molecule that acts by hindering glycolysis and mitochondrial function leading to energy depletion and consequently, to cell death. In this work we have focused on understanding how the glycolytic inhibition affects cancer cell structural features. We showed that 3BP leads to a drastic decrease in the levels of ß-actin and α-tubulin followed by disorganization and shrinkage of the cytoskeleton in breast cancer cells. 3BP inhibits cell migration and colony formation independently of the activity of metalloproteinases. To disclose if these structural alterations occurred prior to 3BP toxic effect, non-toxic concentrations of 3BP were used and we could observe that 3BP was able to inhibit energy production and induce loss of ß-actin and α-tubulin proteins. This was accompanied with alterations in cytoskeleton organization and an increase in E-cadherin levels which may indicate a decrease in cancer cells aggressiveness. In this study we demonstrate that 3BP glycolytic inhibition of breast cancer cells is accompanied by cytoskeleton disruption and consequently loss of migration ability, suggesting that 3BP can potentially be explored for metastatic breast cancer therapy.


Subject(s)
Breast Neoplasms , Tubulin , Actins , Breast Neoplasms/drug therapy , Cell Line, Tumor , Cytoskeleton , Female , Humans , Pyruvates
4.
Opt Lett ; 47(5): 1061-1064, 2022 Mar 01.
Article in English | MEDLINE | ID: mdl-35230290

ABSTRACT

We address the antireflection (AR) properties of periodic surfaces, or metasurfaces, supporting substrate waves. The work is motivated by recent literature where AR bands formed by substrate-wave propagation are incorrectly attributed to Mie scattering. In contrast, as clearly shown here, substrate-wave generation with corresponding AR signatures is a diffractive effect due to a periodic lattice and is not due to particle scattering as in Mie resonance. Treating both 1D and 2D surfaces, we demonstrate a clear quantitative connection between major AR loci and corresponding total substrate transmittance loci via maps in period versus wavelength. As shown, this holds for fully dispersed, lossy surfaces as well. The results presented here serve to elucidate the physical properties of periodic metasurfaces placed on substrates admitting propagating diffraction orders and may inform the design and implementation of grating-based AR structures.

5.
Opt Lett ; 46(6): 1329-1332, 2021 Mar 15.
Article in English | MEDLINE | ID: mdl-33720179

ABSTRACT

The spectral band covering ∼8-12µm is atmospherically transparent and therefore important for terrestrial imaging, day/night situational awareness systems, and spectroscopic applications. There is a dearth of tunable filters spanning the band. Here, we propose and demonstrate a new, to the best of our knowledge, tunable-filter method engaging the fundamental physics of the guided-mode resonance (GMR) effect realized with a non-periodic lattice. The polarization-dependent filter is fashioned with a one-dimensional Ge grating on a ZnSe substrate and interrogated with a ∼1.5mm Gaussian beam to show clear transmittance nulls. To expand the tuning range, the device parameters are optimized for sequential operation in TM and TE polarization states. The theoretical model exhibits a tunable range exceeding 4 µm, thus covering the band fully. In the experiment, a prototype device exhibits a spectral range of 8.6-10.0 µm in TM and 9.9-11.7 µm in TE polarization or >3µm total. With additional efforts in fabrication, we expect to achieve the full range.

6.
Int J Oral Maxillofac Surg ; 50(10): 1280-1288, 2021 Oct.
Article in English | MEDLINE | ID: mdl-33602646

ABSTRACT

Malignant tumours arising from the sublingual glands are very rare, and the extent and frequency of local invasion or regional spread in malignant sublingual gland tumour (MSLT) has not been fully studied due to the disease rarity. To provide comprehensive features of local and regional spread of MSLT, we reviewed 20 surgical cases for detailed pathological analyses among 26 cases diagnosed as having primary MSLT. Adenoid cystic carcinoma (ACC) was the most common pathological subtype, followed by mucoepidermoid carcinoma. Disease-free and overall survivals at 5 years were 76.1 % and 77.7 %, respectively. High-grade malignant tumours and grade 2-3 ACC accounted for 41.7 % and 85.7 %. Clinical and pathological extraparenchymal extensions were found in 34.6 % and 80.0 %, respectively. Tumour invasion to the lingual nerve and submandibular gland/ductal system were also detected in 40.0 % and 28.6 %. The incidences of lingual nerve invasion in ACC and ACC ≥4 cm were 30.8 % and 42.9 %. Regional nodal involvement occurred in seven of 26 cases, and all metastatic lymph nodes were found in neck levels Ib and IIa. In summary, a significant portion of MSLT cases consisted of high-grade tumours and grade 2-3 ACC; therefore local invasion into adjacent structures should be cautiously evaluated in cases of MSLT.


Subject(s)
Carcinoma, Adenoid Cystic , Carcinoma, Mucoepidermoid , Salivary Gland Neoplasms , Sublingual Gland Neoplasms , Carcinoma, Adenoid Cystic/epidemiology , Carcinoma, Adenoid Cystic/surgery , Carcinoma, Mucoepidermoid/surgery , Humans , Neck Dissection , Salivary Gland Neoplasms/surgery , Sublingual Gland Neoplasms/epidemiology , Sublingual Gland Neoplasms/surgery
7.
Opt Lett ; 45(21): 6046-6049, 2020 Nov 01.
Article in English | MEDLINE | ID: mdl-33137065

ABSTRACT

Tunable infrared filters are important for various optical and optoelectronic systems. Ideally, such filters should span wide spectral ranges while retaining constant performance. Here, as a fundamental approach, we theoretically treat tunable resonant filters and realize favorable spectral profiles. Implementing a chirped zero-contrast grating on wedged sublayers, we optimize the resonant tunable filter for operation in the ∼5-14µm band. To clarify the root causes of the physical processes enabling the observed performance, attendant resonance modal processes and background reflection behavior are analyzed in detail by equivalent models as well as by rigorous electromagnetic models. The key innovative contribution of this research is that it enables efficient filters with simultaneously tuned operational wavelengths and sidebands.

8.
Opt Lett ; 45(16): 4452-4455, 2020 Aug 15.
Article in English | MEDLINE | ID: mdl-32796981

ABSTRACT

The long-wave infrared (LWIR) spectral region spanning ∼8-12µm is useful for many scientific and industrial applications. As traditional multilayer film components are not straightforwardly realized at these bands, we provide design, fabrication, and testing of polarization independent bandstop filters based on the guided-mode resonance (GMR) effect. Focusing on the zero-contrast grating architecture, we successfully fabricate prototype filters in the Ge-on-ZnSe materials system. Applying mask-based photolithography and dry etching, photoresist patterns form the desired Ge grating structures. The resulting devices exhibit clean transmittance nulls and acceptably high sidebands. Moreover, we verify polarization independent notch filtering by assembling two identical GMR filters with gratings oriented orthogonally. This approach to realize effective GMR elements will be useful for various fields including photonic and optoelectronic devices operating in the LWIR region.

9.
AJNR Am J Neuroradiol ; 39(4): 762-767, 2018 Apr.
Article in English | MEDLINE | ID: mdl-29371259

ABSTRACT

BACKGROUND AND PURPOSE: Various tumors of the sinonasal tract can exhibit high signal intensity on T1WI. The purpose of this study was to determine the value of a septate pattern on precontrast T1WI for diagnosing sinonasal melanoma. MATERIALS AND METHODS: Retrospectively, 3 observers independently reviewed MR images of 31 histologically proved sinonasal melanomas with special attention to the presence or absence of a septate pattern on precontrast T1WI, defined as alternating hyperintense and hypointense striations on precontrast T1WI. For comparison, we evaluated the prevalence of a septate pattern on precontrast T1WI in 106 nonmelanomatous sinonasal malignant tumors with 16 different histologic types. We also tried to identify the histopathologic features responsible for the septate pattern on precontrast T1WI. RESULTS: Twenty-seven (87.1%) of 31 sinonasal melanomas showed hyperintense foci on T1WI, among which a septate pattern on precontrast T1WI was seen in 23 (74.2%), while 22 (20.8%) of 106 nonmelanomatous malignant tumors demonstrated hyperintense foci on T1WI, among which only 3 (2.8%) showed a septate pattern on precontrast T1WI. The sensitivity, specificity, positive predictive value, negative predictive value, and accuracy of a septate pattern on precontrast T1WI for the diagnosis of sinonasal melanoma were 74%, 97%, 88%, 93%, and 92%, respectively. Although limited due to the retrospective nature, 4 of 23 histologically reviewed sinonasal melanomas revealed an uneven distribution of melanin with alternating melanin and fibrous bands within the tumors. CONCLUSIONS: A septate pattern on precontrast T1WI might be an adjunctive imaging finding for the diagnosis of sinonasal melanoma. This might be attributed histologically to an uneven distribution of melanin and hemorrhage within the tumors.


Subject(s)
Magnetic Resonance Imaging/methods , Melanoma/diagnostic imaging , Nose Neoplasms/diagnostic imaging , Paranasal Sinuses/diagnostic imaging , Adult , Aged , Female , Humans , Male , Melanoma/pathology , Middle Aged , Nose Neoplasms/pathology , Paranasal Sinuses/pathology , Retrospective Studies , Sensitivity and Specificity
10.
Ann Oncol ; 28(9): 2199-2205, 2017 Sep 01.
Article in English | MEDLINE | ID: mdl-28911074

ABSTRACT

BACKGROUND: Current standard treatment, including non-anthracycline-based chemotherapy and optimal combining of radiotherapy, has dramatically improved outcomes of patients with extranodal natural killer/T-cell lymphoma (ENKTL) during the last decade. This study was conducted to investigate the clinical outcome of ENKTL patients with relapsed or progressive disease after initial current standard therapy. PATIENTS AND METHODS: We retrospectively reviewed patients diagnosed with ENKTL at six centers in four countries (China, France, Singapore, and South Korea) from 1997 to 2015 and analyzed 179 patients who had relapsed or progressed after initial current standard therapy. RESULTS: After a median follow-up of 58.6 months (range 27.9-89.2), the median second progression-free survival (PFS) was 4.1 months [95% confidence interval (CI) 3.04-5.16] and overall survival (OS) was 6.4 months (95% CI 4.36-8.51). Multivariate Cox-regression analysis revealed that elevated lactate dehydrogenase, multiple extranodal sites (≥2), and presence of B symptoms were associated with inferior OS (P < 0.05). OS and PFS were significantly different according to both prognostic index of natural killer lymphoma (PINK) and PINK-E (Epstein-Barr virus) models. Salvage chemotherapy with l-asparaginase (l-Asp)-based regimens showed a significantly better clinical benefit to response rate and PFS, although it did not lead to OS improvement. First use of l-Asp in the salvage setting and l-Asp rechallenge at least 6 months after initial treatment were the best candidates for salvage l-Asp containing chemotherapy. CONCLUSIONS: Most patients with relapsed or refractory ENKTL had poor prognosis with short survival. Further studies are warranted to determine the optimal treatment of patients with relapsed or refractory ENKTL.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Lymphoma, Extranodal NK-T-Cell/drug therapy , Adolescent , Adult , Aged , Aged, 80 and over , Anthracyclines/therapeutic use , Antineoplastic Combined Chemotherapy Protocols/administration & dosage , Disease Progression , Female , Humans , Lymphoma, Extranodal NK-T-Cell/pathology , Male , Middle Aged , Recurrence , Salvage Therapy , Treatment Outcome , Young Adult
11.
J Bioenerg Biomembr ; 48(4): 349-62, 2016 08.
Article in English | MEDLINE | ID: mdl-27457582

ABSTRACT

At the beginning of the twenty-first century, 3-bromopyruvate (3BP), a simple alkylating chemical compound was presented to the scientific community as a potent anticancer agent, able to cause rapid toxicity to cancer cells without bystander effects on normal tissues. The altered metabolism of cancers, an essential hallmark for their progression, also became their Achilles heel by facilitating 3BP's selective entry and specific targeting. Treatment with 3BP has been administered in several cancer type models both in vitro and in vivo, either alone or in combination with other anticancer therapeutic approaches. These studies clearly demonstrate 3BP's broad action against multiple cancer types. Clinical trials using 3BP are needed to further support its anticancer efficacy against multiple cancer types thus making it available to more than 30 million patients living with cancer worldwide. This review discusses current knowledge about 3BP related to cancer and discusses also the possibility of its use in future clinical applications as it relates to safety and treatment issues.


Subject(s)
Antineoplastic Agents, Alkylating/therapeutic use , Pyruvates/therapeutic use , Antineoplastic Agents, Alkylating/pharmacology , Enzyme Inhibitors/pharmacology , Enzyme Inhibitors/therapeutic use , Humans , Pyruvates/pharmacology , Translational Research, Biomedical/methods
13.
Leukemia ; 30(6): 1311-9, 2016 06.
Article in English | MEDLINE | ID: mdl-26854024

ABSTRACT

Epitheliotropic intestinal T-cell lymphoma (EITL, also known as type II enteropathy-associated T-cell lymphoma) is an aggressive intestinal disease with poor prognosis and its molecular alterations have not been comprehensively characterized. We aimed to identify actionable easy-to-screen alterations that would allow better diagnostics and/or treatment of this deadly disease. By performing whole-exome sequencing of four EITL tumor-normal pairs, followed by amplicon deep sequencing of 42 tumor samples, frequent alterations of the JAK-STAT and G-protein-coupled receptor (GPCR) signaling pathways were discovered in a large portion of samples. Specifically, STAT5B was mutated in a remarkable 63% of cases, JAK3 in 35% and GNAI2 in 24%, with the majority occurring at known activating hotspots in key functional domains. Moreover, STAT5B locus carried copy-neutral loss of heterozygosity resulting in the duplication of the mutant copy, suggesting the importance of mutant STAT5B dosage for the development of EITL. Dysregulation of the JAK-STAT and GPCR pathways was also supported by gene expression profiling and further verified in patient tumor samples. In vitro overexpression of GNAI2 mutants led to the upregulation of pERK1/2, a member of MEK-ERK pathway. Notably, inhibitors of both JAK-STAT and MEK-ERK pathways effectively reduced viability of patient-derived primary EITL cells, indicating potential therapeutic strategies for this neoplasm with no effective treatment currently available.


Subject(s)
Enteropathy-Associated T-Cell Lymphoma/metabolism , Janus Kinases/metabolism , Receptors, G-Protein-Coupled/metabolism , STAT Transcription Factors/metabolism , Signal Transduction , Adult , Aged , Aged, 80 and over , Cell Survival/drug effects , Cells, Cultured , Enteropathy-Associated T-Cell Lymphoma/pathology , Female , GTP-Binding Protein alpha Subunit, Gi2/genetics , Gene Expression Profiling , Humans , Janus Kinase 3/genetics , Male , Middle Aged , Mutation , Protein Kinase Inhibitors/pharmacology , STAT5 Transcription Factor/genetics , Signal Transduction/drug effects , Young Adult
15.
Bone Marrow Transplant ; 51(6): 807-12, 2016 Jun.
Article in English | MEDLINE | ID: mdl-26855154

ABSTRACT

High-dose chemotherapy and autologous stem cell transplantation (ASCT) for extranodal natural killer/T-cell lymphoma (ENKTL) is a reasonable option for a subset of patients. The impact of response status, according to positron emission tomography/computed tomography (PET/CT) results and/or presence of circulating EBV DNA prior to ASCT, has not yet been established. We analyzed 27 ENKTL patients with pre-ASCT circulating EBV DNA who had undergone pre-ASCT PET/CT between 2009 and 2014. We classified patients into two groups based on the result of pretransplantation assessment: a favorable risk group (pretransplant five-point Deauville score (DS) of 1-2 based on PET/CT and no detectable EBV DNA) and an unfavorable risk group (DS 1-2 with detectable EBV DNA, DS 3-5 with or without detectable EBV DNA). After a median follow-up of 37 months, overall survival and PFS were significantly different between the two groups (median OS: not reached for favorable risk group vs 7.0 months for unfavorable risk group, P=0.017; median PFS: 16.0 vs 5.0 months, P=0.019). Multivariate analysis revealed that pre-ASCT DS and EBV DNA was the only independent prognostic factor considering stage, IPI and NKPI. Precise assessment of the status of disease before transplantation may provide more benefit from ASCT to ENKTL patients.


Subject(s)
DNA, Viral/blood , Hematopoietic Stem Cell Transplantation/methods , Herpesvirus 4, Human/genetics , Lymphoma, Extranodal NK-T-Cell/therapy , Positron Emission Tomography Computed Tomography/methods , Adult , Disease-Free Survival , Female , Hematopoietic Stem Cell Transplantation/mortality , Humans , Lymphoma, Extranodal NK-T-Cell/diagnosis , Lymphoma, Extranodal NK-T-Cell/mortality , Male , Middle Aged , Prognosis , Risk Assessment , Survival Rate , Transplantation, Autologous , Young Adult
16.
Ann Oncol ; 27(4): 712-8, 2016 Apr.
Article in English | MEDLINE | ID: mdl-26861608

ABSTRACT

BACKGROUND: Everolimus, an oral mTOR inhibitor, has single-agent activity against relapsed lymphomas. Thus, we carried out a phase II study of everolimus in combination with CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) as a first-line treatment for patients with peripheral T-cell lymphoma (PTCL) based on our phase I study results. PATIENTS AND METHODS: Participants (n = 30) received CHOP with 5 mg everolimus per day from day 1 to 14 every 21 days for a total of six cycles. The primary end point was the overall response rate (ORR), which included complete response (CR) and partial response (PR) to this regimen. Immunohistochemistry was used to evaluate the expression of phosphatase and tensin homology (PTEN) and phosphorylated S6 kinase (pS6K) as a response. RESULTS: The objective response rate was 90% with CR (n = 17) and PR (n = 10). The CR rate was different among subtypes; angioimmunoblastic T-cell lymphoma (AITL, n = 3) had a CR whereas PTCL-not-otherwise specified and ALK-negative anaplastic large-cell lymphoma (ALCL) patients showed 63% (12/19) and 29% (2/7) of CR rate, respectively. This difference in CR rate among subtypes was associated with PTEN loss because PTEN loss was not seen in AITL but 33% of ALCL patients. The most common toxicity was hematological, with 80% of patients experiencing at least one event of grade 3/4 neutropenia, and 60% of patients had grade 3/4 thrombocytopenia. CONCLUSION: The everolimus plus CHOP was effective for PTCL patients, and its efficacy might be related with the preservation of PTEN.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/administration & dosage , Everolimus/administration & dosage , Lymphoma, T-Cell, Peripheral/drug therapy , PTEN Phosphohydrolase/genetics , Adult , Aged , Antineoplastic Combined Chemotherapy Protocols/adverse effects , Cyclophosphamide/administration & dosage , Cyclophosphamide/adverse effects , Disease-Free Survival , Doxorubicin/administration & dosage , Doxorubicin/adverse effects , Drug Administration Schedule , Everolimus/adverse effects , Female , Humans , Lymphoma, T-Cell, Peripheral/pathology , Male , Middle Aged , Neoplasm Staging , PTEN Phosphohydrolase/biosynthesis , Prednisone/administration & dosage , Prednisone/adverse effects , TOR Serine-Threonine Kinases/antagonists & inhibitors , TOR Serine-Threonine Kinases/genetics , Treatment Outcome , Vincristine/administration & dosage , Vincristine/adverse effects
17.
Ann Oncol ; 27(3): 508-13, 2016 Mar.
Article in English | MEDLINE | ID: mdl-26658891

ABSTRACT

BACKGROUND: Romidepsin, a histone deacetylase (HDAC) inhibitor, has been approved for the treatment of relapsed and refractory peripheral T-cell lymphoma. However, the efficacy and safety of romidepsin has never been studied in patients with relapsed or refractory extranodal natural killer (NK)/T-cell lymphoma (ENKTL). PATIENTS AND METHODS: We conducted an open-label, prospective pilot study to evaluate the efficacy and feasibility of romidepsin in the treatment of patients with ENKTL. The treatment was intravenous infusion of romidepsin (14 mg/m(2)) for 4 h on days 1, 8, and 15 of a 28-day cycle, and was repeated until disease progression or the occurrence of unacceptable toxicity. RESULTS: A total of five patients enrolled on to this pilot study. However, three patients developed fever and elevated liver enzyme and bilirubin levels immediately after their first administration of romidepsin. We suspected that these events were associated with Epstein-Barr virus (EBV) reactivation because of the rapidly elevated EBV DNA titers in blood from these patients. An in vitro study with the ENKTL cell line SNK-6 cells also showed that HDAC inhibitors including romidepsin increased the copy number of EBV DNA in a dose-dependent manner. These findings suggested that romidepsin-induced histone acetylation reversed the repressed state of the genes required for EBV reactivation and that romidepsin treatment may have caused EBV reactivation in EBV-infected tumor cells in ENKTL patients. Therefore, we discontinued the enrollment of patients into this pilot study. CONCLUSIONS: Our study suggests that the use of romidepsin may cause severe EBV reactivation in patients with ENKTL.


Subject(s)
Antibiotics, Antineoplastic/therapeutic use , Depsipeptides/adverse effects , Depsipeptides/therapeutic use , Herpesvirus 4, Human/drug effects , Histone Deacetylase Inhibitors/adverse effects , Lymphoma, Extranodal NK-T-Cell/drug therapy , Virus Activation/drug effects , Antibiotics, Antineoplastic/adverse effects , Cell Line, Tumor , DNA, Viral/blood , Epstein-Barr Virus Infections/pathology , Epstein-Barr Virus Infections/virology , Female , Histone Deacetylase Inhibitors/therapeutic use , Humans , Male , Middle Aged , Pilot Projects , Prospective Studies
18.
Ann Oncol ; 26(3): 548-55, 2015 Mar.
Article in English | MEDLINE | ID: mdl-25475080

ABSTRACT

BACKGROUND: Epstein-Barr virus (EBV)-positive diffuse large B-cell lymphoma (DLBCL) of the elderly is defined only in adults older than 50 years. However, EBV-positive DLBCL can affect younger patients. We investigated the prevalence, clinical characteristics and survival outcomes of EBV-positive DLBCL in young adults. PATIENTS AND METHODS: We analyzed patients with de novo DLBCL who were registered in the Samsung Medical Center (SMC) retrospective lymphoma cohort and prospective SMC Lymphoma Cohort Study I (ClinicalTrials.gov: NCT00822731). RESULTS: A total of 571 cases were included in the analysis. The prevalence of EBV positivity was 6.7% (13/195) and 9.3% (35/376) in the young group (≤50 years) and in the elderly group (>50 years), respectively. EBV status was closely associated with unique unfavorable clinical characteristics [older age, more advanced stage, two or more sites of extranodal involvement, higher International Prognostic Index (IPI), and age-adjusted IPI risk] only in the elderly group. Poor prognostic impact of EBV positivity on overall survival was observed only in the elderly group [hazard ratio (HR) 2.86; 95% confidence interval (CI) 1.83-4.47; P < 0.001], but not in the young group (HR 1.17; 95% CI 0.35-3.89; P = 0.801). CONCLUSION: A substantial proportion of EBV-positive DLBCL of the elderly can occur in young adults. EBV positivity of DLBCL in young adults was not associated with unfavorable clinical characteristics or worse outcomes. We suggest that EBV-positive DLBCL should not be confined only in the elderly and 'EBV-positive DLBCL in young adults' needs to be considered as a clinically distinct disease entity. ClinicalTrials.gov: NCT02060435.


Subject(s)
Epstein-Barr Virus Infections/diagnosis , Epstein-Barr Virus Infections/epidemiology , Herpesvirus 4, Human , Lymphoma, Large B-Cell, Diffuse/diagnosis , Lymphoma, Large B-Cell, Diffuse/epidemiology , Adolescent , Adult , Aged , Aged, 80 and over , Cohort Studies , Female , Follow-Up Studies , Herpesvirus 4, Human/isolation & purification , Humans , Lymphoma, Large B-Cell, Diffuse/virology , Male , Middle Aged , Prospective Studies , Retrospective Studies , Young Adult
19.
Biol Sport ; 31(1): 73-9, 2014 Mar.
Article in English | MEDLINE | ID: mdl-25187675

ABSTRACT

The study investigated the effect of high- and low-intensity exercise training on inflammatory reaction of blood and skeletal muscle in streptozotocin (STZ)-induced diabetic male Sprague-Dawley rats (243 ± 7 g, 8 weeks). The rats completed treadmill running in either high-intensity exercise (6 weeks of exercise training, acute bouts of exercise) or low-intensity exercise (6 weeks of exercise training). Non-running, sedentary rats served as controls. To induce diabetes mellitus, rats received a peritoneal injection of STZ (50 mg · kg(-1)). Rats were sacrificed immediately after an acute bout of exercise and 6 weeks of exercise training. Inflammatory factors were analyzed by ELISA and by immune blotting from the soleus and extensor digitorum longus muscles. In the serum, inflammatory cytokines (IL-1ß, TNF-α, IL-6, IL-4) and reactive oxygen species (ROS) (nitric oxide and malondialdehyde) increased in diabetic rats. However, all exercise training groups displayed reduced inflammatory cytokines and reactive oxygen species. In skeletal muscles, low-intensity exercise training, but not high intensity exercise, reduced the levels of COX-2, iNOS, and MMP-2, which were otherwise markedly elevated in the presence of STZ. Moreover, the levels of GLUT-4 and MyoD were effectively increased by different exercise intensity and exercise duration. Low-intensity exercise training appeared most effective to reduce diabetes-related inflammation. However, high-intensity training also reduced inflammatory factors in tissue-specific muscles. The data implicate regular exercise in protecting against chronic inflammatory diseases, such as diabetes.

20.
Br J Surg ; 101(5): 518-22, 2014 Apr.
Article in English | MEDLINE | ID: mdl-24615472

ABSTRACT

BACKGROUND: Hepatoduodenal lymph node (HDLN) positivity is considered distant metastasis in gastric cancer according to the seventh American Joint Committee on Cancer (AJCC) classification. In contrast, the International Union Against Cancer seventh edition and the Japanese Gastric Cancer Association both consider HDLN as a regional lymph node that can be included in the context of a curative resection. The purpose of this study was to determine whether there was justification for considering HDLN involvement as a distant metastasis for which resectional surgery could not have survival benefit. METHODS: This study enrolled consecutive patients with gastric cancer having D2 or greater resections, with removal and pathological assessment of the HDLN, between 1989 and 2009. The pathological stage of all patients was determined based on the seventh AJCC criteria, with HDLN included as a regional lymph node. RESULTS: A total of 1872 patients had their HDLN removed, of whom 68 had a metastatic lymph node in the hepatoduodenal ligament. The 5-year survival rate of these 68 patients was 30 per cent, compared with 47·7 per cent for those with stage III (P < 0·001) and 9·8 per cent for those with stage IV (P = 0·007) HDLN-negative tumours. The 5-year survival rate of 41 patients with HDLN metastasis and no evidence of distant metastasis at any other site was significantly higher than that among 120 patients with stage IV disease without HDLN metastasis (P < 0·001), whereas 5-year survival did not differ between the 41 patients with stage I-III disease with HDLN metastasis and 568 patients with stage III tumours without HDLN metastasis (P = 0·184). HDLN metastasis was not a significant factor for survival in multivariable analysis. CONCLUSION: It is inappropriate to include the HDLN in the distant metastatic lymph node group in gastric cancer. The seventh AJCC criteria for node grouping should be revised.


Subject(s)
Adenocarcinoma/surgery , Ligaments/surgery , Lymph Nodes/surgery , Stomach Neoplasms/surgery , Adenocarcinoma/mortality , Adenocarcinoma/pathology , Duodenum , Female , Gastrectomy/mortality , Humans , Liver , Lymph Node Excision/methods , Lymphatic Metastasis , Male , Middle Aged , Neoplasm Staging , Prognosis , Stomach Neoplasms/mortality , Stomach Neoplasms/pathology
SELECTION OF CITATIONS
SEARCH DETAIL
...